Teclistamab in Relapsed or Refractory Multiple Myeloma.

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

Who cites it

5 citing papers in PubMed.

1. Bridging Randomized Trial Efficacy and Real-World Effectiveness in Multiple Myeloma: Integrating Clinical Trials and Real-World Evidence for Individualized Care.European journal of haematology · 2026
   Review
2. Haploidentical Hematopoietic Stem Cell Transplantation for Relapsed/Refractory Extramedullary Multiple Myeloma: A Conditioning Regimen Combining Selinexor and Helical Tomotherapy-A Case Report and Literature Review.Journal of blood medicine · 2025
   Article
3. Therapeutic progress in relapsed/refractory multiple myeloma.Annals of hematology · 2024
   Review
4. The present and future of bispecific antibodies for cancer therapy.Nature reviews. Drug discovery · 2024
   Review
5. A pivotal decade for bispecific antibodies?mAbs
   Article

Corrections and comments

• Commented on by
  Teclistamab in Relapsed or Refractory Multiple Myeloma. Reply.2022
• Comment on
  Teclistamab in Relapsed or Refractory Multiple Myeloma.2022

Authors and funding

1 author.

Funding

No grant is acknowledged in the PubMed record.

Abstract

PubMed holds no abstract for this paper.

Indexed as